Get started

Financials · BEAM

Beam Therapeutics Inc. (BEAM) financials

For the twelve months ended Sep 30, 2026, Beam Therapeutics Inc. reported $146.64M of revenue and -$108.35M of net income.

Revenue, TTM
$146.64M
Revenue growth, YoY
+163.3%
Net income, TTM
-$108.35M
Net margin
-73.9%
Free cash flow, TTM
-$398.24M
EPS, diluted, TTM
-$0.85
Cash
$213.27M
Total debt
$100.36M
P/S
19.07
Market cap
$2.80B
Annual revenue$139.74M
FY2019FY2025
Annual net income-$79.99M
FY2019FY2025
Annual free cash flow-$360.05M
FY2019FY2025

BEAM revenue and earnings growth

BEAM revenueQ3 2026$307.0K

Quarter YoY
-96.8%
QoQ
-37.3%
FY YoY
+120.0%
5Y CAGR
+466.3%

BEAM revenue was $307.0K in fiscal Q3 2026 (ended Sep 30, 2026), down 96.8% from a year earlier and down 37.3% from the prior quarter. For the full fiscal 2025 it was $139.74M, up 120.0% from fiscal 2024. Compound annual growth was +466.3% over 5 years. It rose in 5 of the last 6 fiscal years.

BEAM net incomeQ3 2026-$134.41M

BEAM net income was -$134.41M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$112.57M a year earlier. For the full fiscal 2025 it was -$79.99M, compared with -$376.74M in fiscal 2024.

BEAM EPSQ3 2026-$1.28

BEAM diluted EPS was -$1.28 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.10 a year earlier. For the full fiscal 2025 it was -$0.81, compared with -$4.58 in fiscal 2024.

BEAM free cash flowQ3 2026-$111.96M

BEAM free cash flow was -$111.96M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$86.49M a year earlier. For the full fiscal 2025 it was -$360.05M, compared with -$356.19M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$139.74M$63.52M$377.71M$60.92M$51.84M$24.0K$18.0K
Research and development$409.62M$367.56M$437.38M$311.59M$387.09M$103.18M$54.62M
Selling, general and admin$113.82M$111.53M$116.81M$87.81M$57.22M$29.61M$20.55M
Operating income-$383.69M-$415.57M-$176.49M-$338.48M-$392.46M-$132.76M-$75.15M
Pre-tax income-$79.99M-$376.70M-$131.16M-$260.18M-$370.64M-$194.59M-
Income tax$0$39.0K$1.37M$3.41M$0$0$0
Net income-$79.99M-$376.74M-$132.53M-$289.09M-$370.64M-$194.59M-$78.33M
EPS, basic-$0.81-$4.58-$1.72-$4.13-$5.77-$4.19-$14.05
EPS, diluted-$0.81-$4.58-$1.72-$4.13-$5.77-$4.19-$14.05
Diluted shares98.9M82.3M77.2M70.0M64.2M46.7M6.5M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$294.94M$290.11M$435.89M$245.52M$572.74M$177.01M$50.55M
Short-term investments$950.27M$568.77M$753.98M$845.37M---
Current assets$1.27B$878.15M$1.21B$1.09B$1.27B$308.32M$94.54M
Total assets$1.48B$1.10B$1.46B$1.34B$1.47B$451.68M$156.10M
Current liabilities$96.94M$182.07M$205.56M$223.59M$213.44M$102.34M$29.14M
Total liabilities$242.82M$370.28M$478.38M$608.24M$647.72M$206.12M$55.15M
Shareholders' equity$1.24B$733.54M$981.33M$733.47M$826.74M$245.56M-$201.10M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow-$345.10M-$347.25M-$149.19M$22.53M-$66.27M-$95.74M-$72.00M
Capital expenditures$14.95M$8.95M$33.73M$48.95M$46.81M$16.36M$12.52M
Free cash flow-$360.05M-$356.19M-$182.93M-$26.42M-$113.08M-$112.10M-$84.52M
Investing cash flow-$121.44M$185.01M$71.84M-$461.34M-$294.14M-$100.12M-$66.66M
Financing cash flow$478.05M$7.74M$276.45M$111.59M$756.14M$322.32M$41.28M
Stock-based compensation$94.24M$120.66M$98.65M$84.32M$43.57M$15.38M$7.03M
Depreciation and amortization$22.29M$21.93M$20.01M$14.15M$7.45M$4.74M$3.50M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY120.0%-83.2%520.0%17.5%215916.7%33.3%-
Operating margin-274.6%-654.3%-46.7%-555.6%-757.0%-553166.7%-417522.2%
Net margin-57.2%-593.1%-35.1%-474.5%-714.9%-810800.0%-435144.4%
Free cash flow margin-257.7%-560.8%-48.4%-43.4%-218.1%-467075.0%-469561.1%
Return on equity-6.5%-51.4%-13.5%-39.4%-44.8%-79.2%-
Return on assets-5.4%-34.1%-9.1%-21.5%-25.1%-43.1%-50.2%
Current ratio13.094.825.894.895.963.013.24

Source: XBRL data Beam Therapeutics Inc. files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BEAM peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
BEAM$146.64M+163.3%-$108.35M-73.9%$2.80B
CRSP$25.17M-34.3%-$456.13M-1812.1%$4.85B
NTLA$52.89M-8.1%-$426.14M-805.7%$1.70B
EDIT$49.83M+7.4%-$72.22M-145.0%$422.3M
PRME$4.63M+55.3%-$201.14M-4342.4%$779.9M

BEAM FAQ

8 questions
  • What is BEAM revenue?
    Beam Therapeutics Inc. (BEAM) reported $146.64M of revenue for the twelve months ended Sep 30, 2026. That is up 163.3% from the year before. Revenue for fiscal 2025 was $139.74M.
  • Is BEAM profitable?
    No. Beam Therapeutics Inc. reported a net loss of $108.35M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does BEAM have?
    Beam Therapeutics Inc. reported $213.27M in cash and cash equivalents and $100.36M of debt on its most recent balance sheet in SEC filings.
  • How fast is BEAM revenue growing?
    Beam Therapeutics Inc.'s revenue changed +120.0% in fiscal 2025, to $139.74M. Its compound annual growth rate was +466.3% over 5 years.
  • What is BEAM free cash flow?
    Beam Therapeutics Inc. generated -$398.24M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$388.65M less capital expenditures.
  • What is BEAM earnings per share?
    Diluted earnings per share were -$0.85 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did BEAM last report financial results?
    The latest statements here come from Beam Therapeutics Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.
  • Where does this BEAM financial data come from?
    Quantisnow builds these statements from the structured XBRL data Beam Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.